GGrantIndex
← Leaderboards

James G Krueger

Rockefeller University

Google Scholar ↗PubMed ↗ORCID ↗
$4,444,811
Attributed
$4,444,811
Total exposure
30
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $3.7M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$21,912,965 · 31

By mechanism

UL1$17,468,154 · 1
R01$3,309,902 · 3
M01$1,134,909 · 27

Top collaborators

Most similar at Rockefeller University

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject”

Research focus

Human SubjectClinical ResearchPsoriasisHuman Therapy EvaluationSkin Disorder ChemotherapyDrug Screening /EvaluationBiopsyUltraviolet TherapyImmunotherapyLeukocyte Activation /TransformationPatient Oriented ResearchCd AntigensMonoclonal AntibodySkinTissue /Cell CultureT LymphocyteGene ExpressionPhototherapyCytokine ReceptorsInterleukin 2Blood CellsCombination TherapyRecombinant ProteinsHistology

Grant awards (81)

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success$3,671,021
UL1 · FY2025 · TR
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success$3,669,160
UL1 · FY2024 · TR
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success$2,775,381
UL1 · FY2023 · TR
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success$3,681,571
UL1 · FY2022 · TR
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success$3,671,021
UL1 · FY2021 · TR
NATURAL COURSE &HISTORY OF PSORIASIS BEFORE, DURING AND AFTER TREATMENT$217,866
M01 · FY2005 · RR
EFFICACY OF WHOLE BODY NARROWBAND UVB PHOTOTHERAPY (TL-01) IN CAUCASIAN AND DARK$106,784
M01 · FY2005 · RR
MECHANISM OF ACTION OF EFALIZUMAB IN PSORIASIS$105,131
M01 · FY2005 · RR
SCREENING FOR ENTRY INTO PSORIASIS STUDIES$37,358
M01 · FY2005 · RR
COLLECTION OF BLOOD SPECIMENS FOR RESEARCH PURPOSES$29,424
M01 · FY2005 · RR
SAFETY AND PHARMACOLOGY OF HUZAF IN PATIENTS WITH PSORIASIS$15,869
M01 · FY2005 · RR
USE OF HUMANIZED CD25 (ANTI-TAC) AND LOW-DOSE CYCLOSPORINE IN ACTIVE PSORIASIS$7,604
M01 · FY2005 · RR
USE OF HUMANIZED CD25 MONOCLONAL ANTIBODY TO PREVENT RELAPSE OF PSORIASIS$3,967
M01 · FY2005 · RR
EFFECTIVENESS AND SAFETY OF ETANERCEPT IN THE TREATMENT OF PSORIASIS$1,984
M01 · FY2005 · RR
PHARMACODYNAMIC EFFECTS OF CYCLOSPORINE A IN MODERATE-SEVERE PSORIASIS$330
M01 · FY2005 · RR
SKIN BIOPSY FOR ANALYSIS OF CELL GROWTH, CELL DIFFERENTIATION AND INFLAMMATION$330
M01 · FY2005 · RR
Therapeutic immune mechanisms of daclizumab in psoriasis$375,750
R01 · FY2004 · AI
Therapeutic immune mechanisms of anti-CD11a in psoriasis$375,750
R01 · FY2004 · AI
Natural Course &History of Psoriasis Before, During and After Treatment...$239,836
M01 · FY2004 · RR
Use of Humanized CD25 (anti-TAC) and Low-Dose Cyclosporine in Active Psoriasis$117,752
M01 · FY2004 · RR
Efficacy of whole body narrowband UVB phototherapy (TL-01) in Caucasian and dark$76,936
M01 · FY2004 · RR
Collection of Blood Specimens for Research Purposes$54,180
M01 · FY2004 · RR
Use of Humanized CD25 Monoclonal Antibody to Prevent Relapse of Psoriasis$42,621
M01 · FY2004 · RR
Mechanism of action of Efalizumab in psoriasis$30,702
M01 · FY2004 · RR
Pharmacodynamic Effects of Cyclosporine A in Moderate-Severe Psoriasis$24,923
M01 · FY2004 · RR
Screening For Entry Into Psoriasis Studies$20,228
M01 · FY2004 · RR
Comparison of Genes Expressed in Inflammation Arising from Psoriasis$723
M01 · FY2004 · RR
Skin biopsy-Analysis of growth, differentiation &inflam$361
M01 · FY2004 · RR
Therapeutic immune mechanisms of daclizumab in psoriasis$375,750
R01 · FY2003 · AI
Therapeutic immune mechanisms of anti-CD11a in psoriasis$375,750
R01 · FY2003 · AI
Therapeutic immune mechanisms of daclizumab in psoriasis$375,750
R01 · FY2002 · AI
Therapeutic immune mechanisms of anti-CD11a in psoriasis$341,887
R01 · FY2002 · AI
USE OF HUMANIZED CD25 (ANTI-TAC) IN THE TREATMENT OF PSORIASIS$0
M01 · FY2002 · RR
BATH WATER PUVA FOR PSORIASIS AND OTHER T CELL MEDIATED DISEASES$0
M01 · FY2002 · RR
IMMUNOLOGIC STUDIES IN AUTOIMMUNE, ALLERGIC AND CERTAIN OTHER DISEASES$0
M01 · FY2002 · RR
SAFETY, EFFICACY, AND CELLULAR MECHANISMS OF 6 THIOGUANINE IN PSORIASIS$0
M01 · FY2002 · RR
SCREENING FOR ENTRY INTO PSORIASIS STUDIES$0
M01 · FY2002 · RR
NARROWBAND UVB PHOTOTHERAPY FOR PSORIASIS VS. CONVENTIONAL UVB PHOTOTHERAPY$0
M01 · FY2002 · RR
CUTANEOUS CELL RESPONSE TO INJURY FROM EXPOSURE TO TOXIC ENVIRONMENTAL AGENTS$0
M01 · FY2002 · RR
ASSESSMENT OF SAFETY, CLINICAL EFFICACY &CELLULAR MECHANISM OF RHIL 11$0
M01 · FY2002 · RR
PHASE II MULTICENTER STUDY OF SAFETY &EFFICACY OF CP195,543$0
M01 · FY2002 · RR
PHASE I STUDY EXAMINING SURROGATE MARKERS FOR DAB389-IL2 ACTIVITY$0
M01 · FY2002 · RR
RANDOMIZED STUDY COMPARING THE IMMUNOLOGICAL EFFECTS OF NARROWBAND UVB THERAPY$0
M01 · FY2002 · RR
STUDY OF SAFETY &EFFICACY OF ACITRETIN PLUS ULTRAVIOLET B PHOTOTHERAPY$0
M01 · FY2002 · RR
GENES EXPRESSED IN NORMAL OR GROWTH ACTIVATED CELLS$0
M01 · FY2002 · RR
COMPARISON OF GENES EXPRESSED IN INFLAMMATION ARISING FROM PSORIASIS$0
M01 · FY2002 · RR
SAFETY, EFFICACY &DOSING REGIMEN OF NARROWBAND UVB PHOTOTHERAPY (TL-01)$0
M01 · FY2002 · RR
Therapeutic immune mechanisms of anti-CD11a in psoriasis$375,750
R01 · FY2001 · AI
Therapeutic immune mechanisms of daclizumab in psoriasis$338,175
R01 · FY2001 · AI
COMPARISON OF GENES EXPRESSED IN INFLAMMATION ARISING FROM PSORIASIS$0
M01 · FY2001 · RR
GENES EXPRESSED IN NORMAL OR GROWTH ACTIVATED CELLS$0
M01 · FY2001 · RR
STUDY OF SAFETY &EFFICACY OF ACITRETIN PLUS ULTRAVIOLET B PHOTOTHERAPY$0
M01 · FY2001 · RR
RANDOMIZED STUDY COMPARING THE IMMUNOLOGICAL EFFECTS OF NARROWBAND UVB THERAPY$0
M01 · FY2001 · RR
PHASE I STUDY EXAMINING SURROGATE MARKERS FOR DAB389-IL2 ACTIVITY$0
M01 · FY2001 · RR
PHASE II MULTICENTER STUDY OF SAFETY &EFFICACY OF CP195,543$0
M01 · FY2001 · RR
ASSESSMENT OF SAFETY, CLINICAL EFFICACY &CELLULAR MECHANISM OF RHIL 11$0
M01 · FY2001 · RR
USE OF HUMANIZED CD25 (ANTI-TAC) IN THE TREATMENT OF PSORIASIS$0
M01 · FY2001 · RR
CUTANEOUS CELL RESPONSE TO INJURY FROM EXPOSURE TO TOXIC ENVIRONMENTAL AGENTS$0
M01 · FY2001 · RR
NARROWBAND UVB PHOTOTHERAPY FOR PSORIASIS VS. CONVENTIONAL UVB PHOTOTHERAPY$0
M01 · FY2001 · RR
SCREENING FOR ENTRY INTO PSORIASIS STUDIES$0
M01 · FY2001 · RR
SAFETY, EFFICACY, AND CELLULAR MECHANISMS OF 6 THIOGUANINE IN PSORIASIS$0
M01 · FY2001 · RR
IMMUNOLOGIC STUDIES IN AUTOIMMUNE, ALLERGIC AND CERTAIN OTHER DISEASES$0
M01 · FY2001 · RR
BATH WATER PUVA FOR PSORIASIS AND OTHER T CELL MEDIATED DISEASES$0
M01 · FY2001 · RR
SAFETY, EFFICACY &DOSING REGIMEN OF NARROWBAND UVB PHOTOTHERAPY (TL-01)$0
M01 · FY2001 · RR
IMMUNOTHERAPY OF PSORIASIS--MECHANISM OF DAB 389$375,340
R01 · FY2000 · AI
SCREENING FOR ENTRY INTO PSORIASIS STUDIES$0
M01 · FY2000 · RR
IMMUNOLOGIC STUDIES IN AUTOIMMUNE, ALLERGIC AND CERTAIN OTHER DISEASES$0
M01 · FY2000 · RR
CD25 MONOCLONAL ANTIBODY TO PREVENT PSORIASIS VULGARIS$0
M01 · FY2000 · RR
SAFETY, EFFICACY &DOSING REGIMEN OF NARROWBAND UVB PHOTOTHERAPY (TL-01)$0
M01 · FY2000 · RR
COMPARISON OF GENES EXPRESSED IN INFLAMMATION ARISING FROM PSORIASIS$0
M01 · FY2000 · RR
GENES EXPRESSED IN NORMAL OR GROWTH ACTIVATED CELLS$0
M01 · FY2000 · RR
STUDY OF SAFETY &EFFICACY OF ACITRETIN PLUS ULTRAVIOLET B PHOTOTHERAPY$0
M01 · FY2000 · RR
RANDOMIZED STUDY COMPARING THE IMMUNOLOGICAL EFFECTS OF NARROWBAND UVB THERAPY$0
M01 · FY2000 · RR
PHASE I STUDY EXAMINING SURROGATE MARKERS FOR DAB389-IL2 ACTIVITY$0
M01 · FY2000 · RR
BATH WATER PUVA FOR PSORIASIS AND OTHER T CELL MEDIATED DISEASES$0
M01 · FY2000 · RR
PHASE II MULTICENTER STUDY OF SAFETY &EFFICACY OF CP195,543$0
M01 · FY2000 · RR
ASSESSMENT OF SAFETY, CLINICAL EFFICACY &CELLULAR MECHANISM OF RHIL 11$0
M01 · FY2000 · RR
USE OF HUMANIZED CD25 (ANTI-TAC) IN THE TREATMENT OF PSORIASIS$0
M01 · FY2000 · RR
CUTANEOUS CELL RESPONSE TO INJURY FROM EXPOSURE TO TOXIC ENVIRONMENTAL AGENTS$0
M01 · FY2000 · RR
NARROWBAND UVB PHOTOTHERAPY FOR PSORIASIS VS. CONVENTIONAL UVB PHOTOTHERAPY$0
M01 · FY2000 · RR
SAFETY, EFFICACY, AND CELLULAR MECHANISMS OF 6 THIOGUANINE IN PSORIASIS$0
M01 · FY2000 · RR